Compared with standard flu shots, Moderna’s mFlusiva generates stronger, longer-lasting immunity and is more effective at preventing infection, data show.

The FDA’s approval is welcome news, and will hopefully open the door to much faster production of an effective vaccine to counter any future flu pandemic.

Vaccines have been reliably and affordably protecting people from diseases worldwide for centuries. Until the COVID-19 pandemic, however, vaccine development was still a long and idiosyncratic process ...

With clinical success on a personalized mRNA vaccine for melanoma, experts are hoping for a more stable future for the ...

Physicians have been working to treat and study cancer since the days of ancient Egypt. More than 5,000 years later, major progress has been made to treat the disease but scientists still haven't ...

False claims that COVID-19 mRNA vaccines cause cancer could, ironically, lead to worse cancer outcomes by undermining a ...

The flu might be a relatively common illness, but it’s nothing to mess around with. The Centers for Disease Control and Prevention (CDC) estimates that in a typical year, the flu kills tens of ...

For older adults, the flu vaccine could look a little different this year.

The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.

The results from a Merck-Moderna partnership validate years of research into a new approach to cancer treatment.